PB 44 of 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2026

I, Rebecca Richardson, as delegate of the Minister for Health, Disability and Ageing, make the following Determination.

Dated 23 April 2026

Rebecca Richardson

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—Additional designated brands effective from 1 October 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 3

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2026.

 (2) This instrument may also be cited as PB 44 of 2026.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—Additional designated brands effective from 1 October 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Fosamax Plus of the drug Alendronic acid with colecalciferol in the form Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol)

Insert:

2  Section 5 (after table item dealing with the brand Atenolol-AFT of the drug Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL)

Insert:

3  Section 5 (after table item dealing with the brand Carbohydrate Free Mixture of the drug Milk protein and fat formula with vitamins and minerals – carbohydrate free of the form Oral powder 225 g (Carbohydrate Free Mixture))

Insert:

4  Section 5 (after table item dealing with the brand Norimin 28 Day of the drug Norethisterone with ethinylestradiol of the form Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets)

Insert:

5  Section 5 (after table item dealing with the brand OxyNorm of the drug Oxycodone of the form Capsule containing oxycodone hydrochloride 5 mg)

Insert:

6  Section 5 (after table item dealing with the brand Elidel of the drug Pimecrolimus of the form Cream 10 mg per g, 15 g)

Insert:

7  Section 5 (after table item dealing with the brand Vancomycin Viatris of the drug Vancomycin of the form Powder for injection 500 mg (500,000 I.U.) (as hydrochloride))

Insert: